Success Metrics

Active Trials
5(63%)

Phase Distribution

Ph early_phase_1
1
13%
Ph not_applicable
2
25%
Ph phase_2
3
38%
Ph phase_1
2
25%

Phase Distribution

3

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution8 total trials
Early Phase 1First-in-human
1(12.5%)
Phase 1Safety & dosage
2(25.0%)
Phase 2Efficacy & side effects
3(37.5%)
N/ANon-phased studies
2(25.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

5

trials recruiting

Total Trials

8

all time

Status Distribution
Active(5)
Other(3)

Detailed Status

Recruiting5
unknown3

Development Timeline

Analytics

Development Status

Total Trials
8
Active
5
Success Rate
N/A
Most Advanced
Phase 2

Trials by Phase

Early Phase 11 (12.5%)
Phase 12 (25.0%)
Phase 23 (37.5%)
N/A2 (25.0%)

Trials by Status

recruiting563%
unknown338%

Recent Activity

5 active trials
Showing 5 of 8
recruitingphase_1

Autologous Transplantation Combined With BCMA CAR-T in the Treatment of UHR-MM

NCT07109323
recruitingphase_2

MRD-Adaptive Guided Immunotherapy With CAR-T for Transplant-Ineligible Patients With Multiple Myeloma

NCT07106736
recruitingphase_2

ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Ultra-High-Risk Multiple Myeloma

NCT07106710
recruitingphase_2

ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Primary Plasma Cell Leukemia

NCT07106684
recruitingnot_applicable

Exploratory Clinical Study on the Safety and Efficacy of Targeted BCMA Autologous CART Cell Injection in Subjects With Recurrent/Refractory Light Chain Amyloidosis

NCT06983951
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT07109323Phase 1

Autologous Transplantation Combined With BCMA CAR-T in the Treatment of UHR-MM

Recruiting
NCT07106736Phase 2

MRD-Adaptive Guided Immunotherapy With CAR-T for Transplant-Ineligible Patients With Multiple Myeloma

Recruiting
NCT07106710Phase 2

ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Ultra-High-Risk Multiple Myeloma

Recruiting
NCT07106684Phase 2

ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Primary Plasma Cell Leukemia

Recruiting
NCT06983951Not Applicable

Exploratory Clinical Study on the Safety and Efficacy of Targeted BCMA Autologous CART Cell Injection in Subjects With Recurrent/Refractory Light Chain Amyloidosis

Recruiting
NCT04626752Early Phase 1

CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma

Unknown
NCT04447573Not Applicable

Immunotherapy With BCMA CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma

Unknown
NCT03322735Phase 1

Study of BCMA CAR-T in Multiple Myeloma

Unknown

All 8 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
8